Aprea Therapeutics to Host Virtual R&D Day on April 22, 2021

Rhea-AI Summary

Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a virtual R&D Day on April 22, 2021, at 1:00 p.m. ET. This event will feature presentations by CEO Christian S. Schade and CMO Eyal C. Attar, focusing on the results of a completed Phase 3 trial for MDS and ongoing research. Register for the event on Aprea's website, where a replay will be available afterward. Aprea specializes in cancer therapies that reactivate the p53 protein, with its lead candidate, eprenetapopt (APR-246), showing promise in treating various cancers.

BOSTON, April 16, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that it will host a virtual R&D Day at 1:00 p.m. ET on Thursday, April 22, 2021.

Aprea’s R&D Day will be presented by Christian S. Schade, Chairman and Chief Executive Officer, and Eyal C. Attar, Chief Medical Officer, with a focus on the Company’s analysis of its recently completed Phase 3 MDS trial and the continued progress across its ongoing research and clinical development pipeline.

The live webinar will begin at 1:00 pm Eastern Time and last approximately one hour. Registration is accessible on the Events page of Aprea’s website. Following the webinar, a replay will be available for a limited time on Aprea’s website.

About Aprea Therapeutics, Inc.

Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein, p53. The Company’s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors. Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for myelodysplastic syndromes (MDS), Orphan Drug and Fast Track designations from the FDA for acute myeloid leukemia (AML), and Orphan Drug designation from the European Commission for MDS, AML and ovarian cancer. APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration. For more information, please visit the company website at www.aprea.com.

The Company may use, and intends to use, its investor relations website at https://ir.aprea.com/ as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.

About p53, eprenetapopt and APR-548

The p53 tumor suppressor gene is the most frequently mutated gene in human cancer, occurring in approximately 50% of all human tumors. These mutations are often associated with resistance to anti-cancer drugs and poor overall survival, representing a major unmet medical need in the treatment of cancer.

Eprenetapopt (APR-246) is a small molecule that has demonstrated reactivation of mutant and inactivated p53 protein – by restoring wild-type p53 conformation and function – thereby inducing programmed cell death in human cancer cells. Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others. Additionally, strong synergy has been seen with both traditional anti-cancer agents, such as chemotherapy, as well as newer mechanism-based anti-cancer drugs and immuno-oncology checkpoint inhibitors. In addition to pre-clinical testing, a Phase 1/2 clinical program with eprenetapopt has been completed, demonstrating a favorable safety profile and both biological and confirmed clinical responses in hematological malignancies and solid tumors with mutations in the TP53 gene.

A pivotal Phase 3 clinical trial of eprenetapopt and azacitidine for frontline treatment of TP53 mutant MDS has been completed and failed to meet the primary endpoint of complete remission. Additional clinical trials in hematologic malignancies and solid tumors are ongoing. Eprenetapopt has received Breakthrough Therapy, Orphan Drug and Fast Track designations from the FDA for MDS, Orphan Drug and Fast Track designations from the FDA for AML, and Orphan Drug designation from the European Medicines Agency for MDS, AML and ovarian cancer.

APR-548 is a next-generation small molecule p53 reactivator. APR-548 has demonstrated high oral bioavailability, enhanced potency relative to eprenetapopt in TP53 mutant cancer cell lines and has demonstrated in vivo tumor growth inhibition following oral dosing of tumor-bearing mice. Enrollment in a Phase 1 clinical trial of APR-548 is anticipated to begin early in the second quarter of 2021.

Forward-Looking Statement

Certain information contained in this press release includes “forward-looking statements”, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, related to our study analyses, clinical trials, regulatory submissions and projected cash position. We may, in some cases use terms such as “future,” “predicts,” “believes,” “potential,” “continue,” “anticipates,” “estimates,” “expects,” “plans,” “intends,” “targeting,” “confidence,” “may,” “could,” “might,” “likely,” “will,” “should” or other words that convey uncertainty of the future events or outcomes to identify these forward-looking statements. Our forward-looking statements are based on current beliefs and expectations of our management team that involve risks, potential changes in circumstances, assumptions, and uncertainties. Any or all of the forward-looking statements may turn out to be wrong or be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. These forward looking statements are subject to risks and uncertainties including risks related to the success and timing of our clinical trials or other studies, risks associated with the coronavirus pandemic and the other risks set forth in our filings with the U.S. Securities and Exchange Commission. For all these reasons, actual results and developments could be materially different from those expressed in or implied by our forward-looking statements. You are cautioned not to place undue reliance on these forward-looking statements, which are made only as of the date of this press release. We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Source: Aprea Therapeutics, Inc.

Corporate Contacts:

Scott M. Coiante

Sr. Vice President and Chief Financial Officer

617-463-9385

Gregory A. Korbel

Chief Business Officer

617-463-9385

FAQ

What is the date and time of Aprea Therapeutics' R&D Day?

Aprea Therapeutics will host its R&D Day on April 22, 2021, at 1:00 p.m. ET.

Who will present at Aprea's R&D Day?

The R&D Day will feature presentations by Christian S. Schade, CEO, and Eyal C. Attar, CMO.

What will be discussed during the R&D Day?

The event will focus on Aprea's Phase 3 MDS trial results and updates on their research pipeline.

How can I register for Aprea's R&D Day?

Registration is available on Aprea Therapeutics' Events page on their website.

What is eprenetapopt and its significance?

Eprenetapopt (APR-246) is Aprea's lead candidate aimed at reactivating the p53 tumor suppressor protein to treat various cancers.

What recent clinical trials has Aprea conducted?

Aprea recently completed a Phase 3 clinical trial for eprenetapopt in treating MDS, although it did not meet its primary endpoint.

What designations has eprenetapopt received from the FDA?

Eprenetapopt has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA for MDS and AML.